Drug updated on 11/15/2023
|Injection (intramuscular; 600 mg/3mL, 400 mg/2mL)
|Ongoing and Completed Studies
- For the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Product Monograph / Prescribing Information
|Cabenuva (cabotegravir/rilpivirine) Prescribing Information.
|ViiV Healthcare, Research Triangle Park, NC
Systematic Reviews / Meta-Analyses
|Safety and efficacy of long-acting injectable agents for hiv-1: systematic review and meta-analysis.
|JMIR Public Health and Surveillance
|Cabotegravir with rilpivirine for treating HIV-1.
|Australian public assessment report for cabotegravir sodium and cabotegravir/rilpivirine.
|Australian Government: Department of Health
|Safety and pharmacokinetic profiles of long-acting injectable antiretroviral drugs for HIV-1 pre-exposure prophylaxis: a systematic review and meta-analysis of randomized trials.
|Frontiers in Pharmacology
|Clinical guidance report: cabotegravir tablets, cabotegravir extended-release injectable suspension and rilpivirine extended-release injectable suspension.